Postinfectious Irritable Bowel Syndrome and Gelsectan
Key facts
- Who runs it
- Evangelismos Hospital
- Where
- Greece1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 275 people enrolled
- Started
- 1 Sept 2021
- Ended
- 26 Feb 2024
- Type of study
- Interventional
- Treatments tested
- (Gelsectan, Devintec Sagl)
- Record updated
- 28 February 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients with diarrhea-predominant post-infectious IBSand patients with diarrhea predominant classical IBS (non PI-IBS) who will be used as controls
- Diagnosis of IBS will be made according to the ROME iV criteria as following:
- Recurrent abdominal pain, on average, at least 1 day/week in the last 3 months, associated with two or more of the following criteria:
- Related to defecation
- Associated with a change in frequency of stool
- Associated with a change in form (appearance) of stool. The above-mentioned criteria have to be fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis; Diagnosis of post infectious IBS will be made according to the Rome Foundation Working Team criteria as following:; Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, with symptom onset at least 6 months before diagnosis, associated with two of the following:
- defecation
- a change in frequency of stool
- a change in form (appearance) of stool Symptom development immediately after resolution of acute infectious gastroenteritis; Infectious gastroenteritis should be defined by positive stool culture in a symptomatic individual or presence of two of the following acute symptoms (when stool culture not available):
- fever
- vomiting
- diarrhea
Who cannot take part
- Patients should not meet criteria for IBS before onset of acute illness
- We will exclude patients who are pregnant, who have an oncology history (since these patients might exhibit diarrhea due to their underlying illness) and patients with alcohol dependence (due to the non-compliance shown by these patients) and patients with known hypersensitivity or allergy to any of the ingredients included in Gelsectan
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Irritable Bowel Syndrome (IBS) is one of the most common conditions diagnosed in gastroenterology practice. Acute infectious gastroenteritis represents the strongest known risk factor for IBS development; a condition known as post-infection IBS (PI-IBS). PI-IBS patients are more likely than sporadic IBS patients to exhibit a diarrhea-predominant phenotype. The investigators plan to prospectively recruit two groups of patients: patients with diarrhea-predominant post-infectious IBSand patients with diarrhea predominant classical IBS (non PI-IBS) who will be used as controls.
Read full original descriptionShow less
Patients included in the study will receive for 28 days a capsule containing Tamarind seed polysaccharide containing xyloglucan, combined with a pea protein reticulated with grape seed extractand a prebiotic, the xilooligosaccharide (Gelsectan, Devintec Sagl) twice daily.
The group in the trial
- Postinfectious ibs and diarrhea predominant classical IBSTreatment being tested
Capsule containing Tamarind seed polysaccharide containing xyloglucan, combined with a pea protein reticulated with grape seed extractand a prebiotic, the xilooligosaccharide (Gelsectan, Devintec sagl) twice daily
Treatment: (Gelsectan, Devintec Sagl)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Treatment of Postinfectious Irritable Bowel Syndrome and Noninfective Irritable Bowel Syndrome With Gelsectan
- Record updated
- 28 February 2024